(doxorubicin hydrochloride)

Prescribing Information
Download Prescribing Information

HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use DOXORUBICIN HYDROCHLORIDE safely and effectively. See full prescribing information for DOXORUBICIN HYDROCHLORIDE.

DOXORUBICIN HYDROCHLORIDE injection, for intravenous use
Initial U.S. Approval: 1974

WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION

See full prescribing information for complete boxed warning.

•
Cardiomyopathy: Myocardial damage can occur with doxorubicin hydrochloride with incidences from 1%–20% for cumulative doses from 300 mg/m2 to 500 mg/m2 when doxorubicin hydrochloride is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with doxorubicin hydrochloride. (5.1)
•
Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin hydrochloride. (5.2)
•
Extravasation and Tissue Necrosis: Extravasation of doxorubicin hydrochloride can result in severe local tissue injury and necrosis requiring wide excision and skin grafting. Immediately terminate the drug, and apply ice to the affected area. (5.3)
•
Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur. (5.4)

INDICATIONS AND USAGE

Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated:

•
as a component of multi‑agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1)
•
for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2)

DOSAGE AND ADMINISTRATION

•
Single agent: 60 to 75 mg/m2 given intravenously every 21 days (2.2)
•
In combination: 40 to 75 mg/m2 given intravenously every 21 to 28 days (2.2)
•
Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy (2.3)
•
Reduce dose in patients with hepatic impairment (2.4)

DOSAGE FORMS AND STRENGTHS

Injection:

o
10 mg/5 mL, 20 mg/10 mL, 50 mg/25 mL in single-dose vial (3)
o
150 mg/75 mL, and 200 mg/100 mL in multiple-dose vial (3)

CONTRAINDICATIONS

•
Severe myocardial insufficiency (4)
•
Recent myocardial infarction (4)
•
Severe persistent drug-induced myelosuppression (4)
•
Severe hepatic impairment (4)
•
Severe hypersensitivity to doxorubicin hydrochloride (4)

WARNINGS AND PRECAUTIONS

•
Radiation-Induced Toxicity: Can be increased by the administration of Doxorubicin Hydrochloride Injection. Radiation recall can occur in patients who receive Doxorubicin Hydrochloride Injection after prior radiation therapy. (5.7)
•
Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and on the use of effective contraception. Advise males with female partners of reproductive potential to use effective contraception. Advise males with pregnant partners to use condoms. (5.8, 8.1, 8.3)

ADVERSE REACTIONS

The most common (>10%) adverse reactions are alopecia, nausea and vomiting. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

•
Avoid concomitant use of doxorubicin hydrochloride with inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp (7.1)
•
Do not administer doxorubicin hydrochloride in combination with trastuzumab due to increased risk of cardiac dysfunction (5.1, 7.2)

USE IN SPECIFIC POPULATIONS

•
Lactation: Advise not to breastfeed (8.2)
•
Females and Males of Reproductive Potential: May impair fertility (8.3)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 7/2024

Medication Guide

MEDICATION GUIDE

Patient Information

DOXORUBICIN (dok-suh-roo-buh-sin) HYDROCHLORIDE
injection, for intravenous use

What is the most important information I should know about Doxorubicin?

Doxorubicin may cause serious side effects including:

•
Heart muscle problems. Doxorubicin can cause heart muscle damage that may lead to heart failure. Heart failure means your heart does not pump blood well. Heart failure is irreversible in some cases and can lead to death. Heart failure can happen during your treatment with Doxorubicin or months to years after stopping treatment. Your risk of heart muscle damage increases with higher total amounts of Doxorubicin that you receive in your lifetime. Your risk of heart failure is higher if you:
o
have other heart problems
o
have had or are currently receiving radiation therapy to your chest
o
have had treatment with certain other anti-cancer medicines
o
take other medicines that can have severe side effects on your heart

Tell your healthcare provider if you get any of these symptoms of heart failure during or after treatment with Doxorubicin:

o
extreme tiredness or weakness
o
shortness of breath
o
fast heartbeat
o
swelling of your feet and ankles

Your healthcare provider will do tests to check the strength of your heart muscle before, during, and after your treatment with Doxorubicin.

•
Heart rhythm problems. Doxorubicin can cause serious heart rhythm problems that may lead to death. This can happen during your infusion, within a few hours after your infusion or anytime during treatment with Doxorubicin. Tell your healthcare provider if you get any symptoms of heart rhythm problems, such as feeling as if your heart is beating fast, irregular or slow, or you feel lightheaded, dizzy, short of breath, chest discomfort or you faint.
•
Risk of new cancers. You may have an increased risk of developing certain blood cancers called acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) after treatment with Doxorubicin. Talk with your healthcare provider about your risk of developing new cancers if you receive Doxorubicin.
•
Skin damage at or near the vein where Doxorubicin is given. Doxorubicin can damage the skin if it leaks out of the vein and might cause blisters, skin sores or severe tissue damage, which may require skin grafts. Tell your healthcare provider if you get burning or stinging during your infusion.
•
Decreased blood cell counts. Doxorubicin can cause a decrease in neutrophils (a type of white blood cell important in fighting bacterial infections) and platelets (important for clotting and to control bleeding). This may lead to a serious infection, the need for blood transfusions, treatment in a hospital or death. Your healthcare provider will check your blood cell counts before each infusion and during treatment with Doxorubicin. Call your healthcare provider right away if you get a fever (temperature of 100.4°F or higher) or chills with shivering.

What is Doxorubicin?

Doxorubicin is a prescription medicine used to treat certain types of cancers. Doxorubicin may be used alone or along with other anti-cancer medicines.

Do not receive Doxorubicin if:

•
you have had a recent heart attack (within the past 4 to 6 weeks) or have severe heart problems.
•
your blood cell counts (platelets, red blood cells, and white blood cells) are very low because of prior chemotherapy.
•
you have severe liver problems.
•
you have had a severe allergic reaction to Doxorubicin.

Before you receive Doxorubicin, tell your healthcare provider about all of your medical conditions, including if you:

•
have heart problems including heart failure.
•
are currently receiving radiation therapy or plan to receive radiation to the chest.
•
have liver problems.
•
have had an allergic reaction to doxorubicin.
•
are pregnant or plan to become pregnant. Doxorubicin can harm your unborn baby. You should not become pregnant during treatment with Doxorubicin. Tell your healthcare provider right away if you become pregnant or think you may be pregnant.
Females who are able to become pregnant:
o
Your healthcare provider will check to see if you are pregnant before you start treatment with Doxorubicin.
o
You should use effective birth control (contraception) during treatment with Doxorubicin and for 6 months after treatment.
 
Males:
o
Doxorubicin can affect your sperm and could cause birth defects.
o
If you have a female partner who can become pregnant, you should use effective birth control during treatment with Doxorubicin and for 3 months after treatment.
o
If you have a pregnant partner, you should use condoms during treatment with Doxorubicin and for at least 10 days after the final dose.
o
Talk to your healthcare provider about birth control methods that may be right for you.
•
are breastfeeding or plan to breastfeed. Doxorubicin can pass into your breast milk. Do not breastfeed during treatment with Doxorubicin and for 10 days after the final dose. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive Doxorubicin?

•
Doxorubicin will be given to you into your vein through an intravenous (IV) line.
•
Your healthcare provider will do blood tests to check for side effects during treatment with Doxorubicin.
•
Your healthcare provider may stop your treatment, change the timing of your treatment, or change the dose of your treatment if you have certain side effects while receiving Doxorubicin.

What are the possible side effects of Doxorubicin?

Doxorubicin may cause serious side effects, including:

•
See “What is the most important information I should know about Doxorubicin?”

The most common side effects of Doxorubicin include:

•
total hair loss (alopecia). Your hair may re-grow after your treatment.
•
nausea
•
vomiting

Other side effects:

•
Red colored urine. You may have red colored urine for 1 to 2 days after your infusion of Doxorubicin. This is normal. Tell your healthcare provider if it does not stop in a few days, or if you see what looks like blood or blood clots in your urine.
•
Call your healthcare provider if you have severe symptoms that prevent you from eating or drinking, such as:
o
nausea
o
vomiting
o
diarrhea
o
mouth pain or sores

Doxorubicin may cause fertility problems in males. This could affect your ability to father a child. Talk to your healthcare provider if this is a concern for you.

Doxorubicin may cause fertility problems in females. Your periods (menstrual cycle) may completely stop when you receive Doxorubicin. Your periods may or may not return following treatment. Early menopause has also happened. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of Doxorubicin.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of Doxorubicin.


Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.

You can ask your pharmacist or healthcare provider for information about Doxorubicin that is written for health professionals.

What are the ingredients in Doxorubicin?

Active ingredient: doxorubicin hydrochloride

Inactive ingredients for Doxorubicin Hydrochloride Injection: sodium chloride, and hydrochloric acid, USP.

Logo

LAB-0436-5.0


For more information, call 1-800-438-1985 or visit www.pfizer.com.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Revised: 7/2024

Additional Resources

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.

Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.

Available 9AM-5PM ET Monday to Friday; excluding holidays.

 

Submit a medical question for a Pfizer medicine or a vaccine. 

The submission will be reviewed during our standard business hours.

To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information: 
Pfizer Safety Reporting Site

*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.

If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.